name Lucentis) is a monoclonal antibody fragment derived from
the same parent mouse antibody as Bevacizumab
(Avastin). It is much smaller than the parent molecule Avastin; it has been
manufactured to provide stronger binding to Vascular
Endothelial Growth Factor (VEGF).
Ranibizumab binds to and
inhibits a number of subtypes of VEGF. VEGF triggers the growth of new vessels,
which may leak blood and fluid into the retina. These leaky blood
vessels result in the wet type of AMD.
Prior to Lucentis intravitreal treatment (left), subretinal fluid (black area under retina profile) is present.
One month after treatment (right), subretinal fluid has resorbed.